Sciele takeover nets veteran reps

Share this article:
With its acquisition of Sciele Pharma, Osaka, Japan-based Shionogi & Co. will gain immediate entry into the US pharmaceutical market and inherit 720 seasoned sales reps. 

Under the terms of the agreement, Shionogi will acquire Sciele for $1.1 billion. Upon approval, Sciele will become a wholly owned subsidiary and will continue operating from its Atlanta headquarters as a standalone unit. The acquisition is not expected to result in the reduction of Sciele employees.

Shionogi will acquire five products in Phase II development or later by the end of 2009. The acquisition is expected to be completed by the fourth quarter of this year.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"